8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Paediatric patients with cancer and those undergoing haematopoietic cell transplantation are at high risk of bacterial infections. The 8th European Conference on Infections in Leukaemia (ECIL-8) convened a Paediatric Group to review the literature and to formulate recommendations for the use of antibiotics according to the European Society of Clinical Microbiology and Infectious Diseases grading system. The evaluation of antibacterial prophylaxis included mortality, bloodstream infection, febrile neutropenia, emergence of resistance, and adverse effects as endpoints. Initial antibacterial therapy and antibiotic de-escalation or discontinuation focused on patients with a clinically stable condition and without previous infection or colonisation by resistant bacteria, and on patients with a clinically unstable condition or with previous infection or colonisation by resistant bacteria. The final considerations and recommendations of the ECIL-8 Paediatric Group on antibacterial prophylaxis, initial therapy, and de-escalation strategies are summarised in this Policy Review.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): June 2021

Volume: 22

Issue: 6

Affiliations

[1 ] Pediatric Hematology and Oncology, Hospital for Children and Adolescents, Johann Wolfgang Goethe University, Frankfurt, Germany. Electronic address: thomas.lehrnbecher@kgu.de.

[2 ] Department of Pediatrics, Hadassah Hebrew University Medical Center, Jerusalem, Israel.

[3 ] Infectious Diseases Unit, Department of Pediatrics, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

[4 ] Pediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

[5 ] Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, Bern University Hospital, Bern, Switzerland.

[6 ] Department of Infectious Diseases, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain; IDIBAPS, University of Barcelona, Barcelona, Spain.

[7 ] Division of Hematology-Oncology and Stem Cell Transplantation, New Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

[8 ] Infectious Diseases Unit, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris, Paris, France.

[9 ] Division of Infectious Diseases, Department of Health Sciences, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

[10 ] Department of Medicine, European University of Cyprus, Nicosia, Cyprus.

[11 ] Pediatric Infectious Diseases and Vaccinology, University of Basel Children's Hospital, Basel, Switzerland.

[12 ] Department of Infectious Diseases and National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

[13 ] Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.

[14 ] MRC Centre for Medical Mycology, University of Exeter, Exeter, UK.

[15 ] Infectious Disease Research Program, Center for Bone Marrow Transplantation, Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.

Article

Publisher Item ID: S1470-2045(20)30725-7

DOI: 10.1016/S1470-2045(20)30725-7

PubMed ID: 33811814

SO-VID: 224294c6-8e97-4096-86b3-431d56d8349a

History

Data availability:

Comments

Comment on this article

scite_

Cited by 26

See all cited by